Cystic fibrosis: NHLBI workshop on the primary prevention of chronic lung diseases

Jessica E. Pittman, Garry Cutting, Stephanie Davis, Thomas Ferkol, Richard Boucher

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Cystic fibrosis (CF) is a life-limiting, monogenic disorder characterized by chronic sinopulmonary and gastrointestinal involvement. Progressive pulmonary disease leads to death in the majority of patients. Despite its well-defined molecular basis related to defects in the cystic fibrosis transmembrane conductance regulator anion transport channel, there are large gaps in our understanding of the origin of CF lung disease. Disease has been shown to be present in infancy, and there is mounting evidence that abnormalities begin in utero. Heterogeneity of clinical presentations and severity suggest that many factors involved in lung disease have yet to be fully elucidated. Although new advances in therapeutic treatments have shown promise in delaying disease progression, the prevention of pulmonary disease at its origin (primary prevention) should be a key goal of CF care. The objective of this workshop was to (1) review our understanding of the origins of CF lung disease, (2) determine gaps in the knowledge base that are most significant and most likely to enable prevention of CF lung disease, and (3) prioritize new research questions that will promote pulmonary health in both CF and other childhood lung diseases. The goal of this report is to provide recommendations for future research that will improve our understanding of pulmonary development in health and disease, improve outcome measures and biomarkers for early lung disease, and determine therapeutic targets and strategies to prevent the development of lung disease in children with CF.

Original languageEnglish
JournalAnnals of the American Thoracic Society
Volume11
Issue numberSUPPL. 3
DOIs
StatePublished - 2014

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Primary Prevention
Cystic Fibrosis
Lung Diseases
Chronic Disease
Education
Cystic Fibrosis Transmembrane Conductance Regulator
Lung
Knowledge Bases
Health
Anions
Disease Progression
Therapeutics
Biomarkers
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Cystic fibrosis : NHLBI workshop on the primary prevention of chronic lung diseases. / Pittman, Jessica E.; Cutting, Garry; Davis, Stephanie; Ferkol, Thomas; Boucher, Richard.

In: Annals of the American Thoracic Society, Vol. 11, No. SUPPL. 3, 2014.

Research output: Contribution to journalArticle

Pittman, Jessica E. ; Cutting, Garry ; Davis, Stephanie ; Ferkol, Thomas ; Boucher, Richard. / Cystic fibrosis : NHLBI workshop on the primary prevention of chronic lung diseases. In: Annals of the American Thoracic Society. 2014 ; Vol. 11, No. SUPPL. 3.
@article{3f5a8090124d42a784cecb73de097a1a,
title = "Cystic fibrosis: NHLBI workshop on the primary prevention of chronic lung diseases",
abstract = "Cystic fibrosis (CF) is a life-limiting, monogenic disorder characterized by chronic sinopulmonary and gastrointestinal involvement. Progressive pulmonary disease leads to death in the majority of patients. Despite its well-defined molecular basis related to defects in the cystic fibrosis transmembrane conductance regulator anion transport channel, there are large gaps in our understanding of the origin of CF lung disease. Disease has been shown to be present in infancy, and there is mounting evidence that abnormalities begin in utero. Heterogeneity of clinical presentations and severity suggest that many factors involved in lung disease have yet to be fully elucidated. Although new advances in therapeutic treatments have shown promise in delaying disease progression, the prevention of pulmonary disease at its origin (primary prevention) should be a key goal of CF care. The objective of this workshop was to (1) review our understanding of the origins of CF lung disease, (2) determine gaps in the knowledge base that are most significant and most likely to enable prevention of CF lung disease, and (3) prioritize new research questions that will promote pulmonary health in both CF and other childhood lung diseases. The goal of this report is to provide recommendations for future research that will improve our understanding of pulmonary development in health and disease, improve outcome measures and biomarkers for early lung disease, and determine therapeutic targets and strategies to prevent the development of lung disease in children with CF.",
author = "Pittman, {Jessica E.} and Garry Cutting and Stephanie Davis and Thomas Ferkol and Richard Boucher",
year = "2014",
doi = "10.1513/AnnalsATS.201312-444LD",
language = "English",
volume = "11",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Cystic fibrosis

T2 - NHLBI workshop on the primary prevention of chronic lung diseases

AU - Pittman, Jessica E.

AU - Cutting, Garry

AU - Davis, Stephanie

AU - Ferkol, Thomas

AU - Boucher, Richard

PY - 2014

Y1 - 2014

N2 - Cystic fibrosis (CF) is a life-limiting, monogenic disorder characterized by chronic sinopulmonary and gastrointestinal involvement. Progressive pulmonary disease leads to death in the majority of patients. Despite its well-defined molecular basis related to defects in the cystic fibrosis transmembrane conductance regulator anion transport channel, there are large gaps in our understanding of the origin of CF lung disease. Disease has been shown to be present in infancy, and there is mounting evidence that abnormalities begin in utero. Heterogeneity of clinical presentations and severity suggest that many factors involved in lung disease have yet to be fully elucidated. Although new advances in therapeutic treatments have shown promise in delaying disease progression, the prevention of pulmonary disease at its origin (primary prevention) should be a key goal of CF care. The objective of this workshop was to (1) review our understanding of the origins of CF lung disease, (2) determine gaps in the knowledge base that are most significant and most likely to enable prevention of CF lung disease, and (3) prioritize new research questions that will promote pulmonary health in both CF and other childhood lung diseases. The goal of this report is to provide recommendations for future research that will improve our understanding of pulmonary development in health and disease, improve outcome measures and biomarkers for early lung disease, and determine therapeutic targets and strategies to prevent the development of lung disease in children with CF.

AB - Cystic fibrosis (CF) is a life-limiting, monogenic disorder characterized by chronic sinopulmonary and gastrointestinal involvement. Progressive pulmonary disease leads to death in the majority of patients. Despite its well-defined molecular basis related to defects in the cystic fibrosis transmembrane conductance regulator anion transport channel, there are large gaps in our understanding of the origin of CF lung disease. Disease has been shown to be present in infancy, and there is mounting evidence that abnormalities begin in utero. Heterogeneity of clinical presentations and severity suggest that many factors involved in lung disease have yet to be fully elucidated. Although new advances in therapeutic treatments have shown promise in delaying disease progression, the prevention of pulmonary disease at its origin (primary prevention) should be a key goal of CF care. The objective of this workshop was to (1) review our understanding of the origins of CF lung disease, (2) determine gaps in the knowledge base that are most significant and most likely to enable prevention of CF lung disease, and (3) prioritize new research questions that will promote pulmonary health in both CF and other childhood lung diseases. The goal of this report is to provide recommendations for future research that will improve our understanding of pulmonary development in health and disease, improve outcome measures and biomarkers for early lung disease, and determine therapeutic targets and strategies to prevent the development of lung disease in children with CF.

UR - http://www.scopus.com/inward/record.url?scp=84899046260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899046260&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201312-444LD

DO - 10.1513/AnnalsATS.201312-444LD

M3 - Article

C2 - 24754825

AN - SCOPUS:84899046260

VL - 11

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - SUPPL. 3

ER -